Cynda(SH:603086)2025-10-28 09:05Financial Performance - The company's operating revenue for the third quarter was ¥585,734,066.27, a decrease of 5.59% compared to the same period last year[5]. - The total profit for the quarter reached ¥63,314,503.77, reflecting a significant increase of 2,713.63% year-on-year[5]. - The net profit attributable to shareholders was ¥59,849,117.52, up 5,447.46% compared to the previous year[5]. - Total operating revenue for the first three quarters of 2025 reached ¥2,008,351,377.31, an increase of 6.1% compared to ¥1,892,633,164.64 in the same period of 2024[19]. - Net profit for the first three quarters of 2025 was ¥195,631,230.18, significantly up from ¥7,323,288.67 in the previous year, marking a growth of 2670.5%[20]. - Basic and diluted earnings per share for the period were both ¥0.45, compared to ¥0.01 in the same period last year[21]. - The company achieved a comprehensive income total of ¥195,636,006.37, compared to ¥7,323,288.67 in the previous year[21]. Cash Flow - The net cash flow from operating activities for the year-to-date was -¥129,673,773.47, indicating a decline of 445.56%[5]. - Cash inflow from operating activities totaled ¥1,528,086,052.96, an increase from ¥1,490,517,316.33 in the first three quarters of 2024[23]. - Net cash flow from operating activities decreased to -$129.67 million from $37.53 million year-over-year[24]. - Cash inflow from investment activities increased to $2.36 billion from $1.74 billion year-over-year[24]. - Cash outflow for investment activities rose to $2.62 billion from $2.01 billion year-over-year[24]. - Net cash flow from financing activities improved to $308.47 million from $21.71 million year-over-year[24]. - The net increase in cash and cash equivalents was -$75.13 million compared to -$208.99 million year-over-year[24]. - The ending balance of cash and cash equivalents was $236.68 million, up from $210.63 million year-over-year[24]. - Cash received from borrowings increased to $651.51 million from $344.70 million year-over-year[24]. - Cash paid for debt repayment was $329.50 million, slightly up from $314.50 million year-over-year[24]. - Cash inflow from investment income decreased to $2.74 million from $4.52 million year-over-year[24]. - Cash paid for fixed assets and intangible assets was $127.16 million, up from $94.39 million year-over-year[24]. Assets and Liabilities - The total assets at the end of the reporting period were ¥3,979,619,930.50, an increase of 4.87% from the end of the previous year[6]. - As of September 30, 2025, the total current assets amounted to RMB 2,455,779,932.64, an increase from RMB 2,197,868,376.20 as of December 31, 2024, representing a growth of approximately 11.7%[15]. - The company's cash and cash equivalents decreased to RMB 554,166,284.44 from RMB 675,793,463.51, a decline of about 18%[15]. - Accounts receivable increased to RMB 562,624,483.44 from RMB 450,291,292.77, reflecting a growth of approximately 25%[15]. - Inventory rose to RMB 899,805,061.06 from RMB 794,287,047.80, indicating an increase of around 13.3%[15]. - Total liabilities increased to RMB 2,155,780,000.00, up from RMB 1,800,000,000.00, marking a rise of approximately 19.8%[16]. - Short-term borrowings surged to RMB 749,755,923.84 from RMB 427,415,025.83, representing an increase of about 75%[16]. - The total assets of the company reached RMB 3,979,619,930.50, compared to RMB 3,794,888,193.90, showing an increase of approximately 4.9%[16]. - The company's non-current assets decreased to RMB 1,523,839,997.86 from RMB 1,597,019,817.70, a decline of about 4.6%[16]. - The total liabilities decreased to ¥1,811,174,785.68 from ¥1,819,332,833.25, indicating a reduction of 0.9%[19]. - The total equity attributable to shareholders increased to ¥2,161,050,577.43 from ¥1,967,903,236.32, reflecting a growth of 9.8%[19]. Operational Insights - The increase in net profit was primarily driven by the significant rise in market prices for the company's main product, acetochlor, and the introduction of new products[10]. - The company experienced a net loss in cash flow due to increased raw material reserves required for new production capacity[10]. - Non-recurring gains and losses for the quarter totaled ¥3,536,432.05, with government subsidies contributing ¥4,124,493.70[8]. - Research and development expenses were ¥77,202,836.62, slightly down from ¥79,689,256.62 in the same period last year[19]. - The company has not reported any significant changes in shareholder structure or major financing activities during the reporting period[14].